linjc16/ctgov huggingface dataset:
Gut Hormones and Bone Remodeling in Humans (KS-2)

Study Overview
=================
Brief Summary
-----------------
Effects of GLP-2 and GIP on bone remodeling in healthy young men.

Detailed Description
-----------------
We will investigate acute effects of GLP-2 and GIP on bone remodeling in healthy young men.

Official Title
-----------------
Investigation of GLP-2 Mechanism of Action (KS-2)

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: GLP-2
* Other: GIP
* Other: GLP-2+GIP
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 20 and 40 years old Caucasian Healthy BMI between 18.5 and 24.9 kg/m2. Exclusion Criteria: Chronic disease Smoking Medication Weight change more than 3 kg whitin the last 3 months Overweight surgery Intestinal surgery Hgb<8,0 mmol/L Decreased renal function.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GLP-2<br>Glucagon-Like Peptide-2 (GLP-2) injection | Other: GLP-2<br>* GLP-2<br>|
| Experimental: GIP<br>Glucose-dependent Insulinotropic polypeptide (GIP) injection | Other: GIP<br>* GIP<br>|
| Experimental: GLP-2+GIP<br>GLP-2+GIP injection | Other: GLP-2+GIP<br>* GLP-2+GIP<br>|
| Placebo Comparator: Placebo<br>Placebo injection | Other: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone resorption | C-terminal telopeptide (CTX) is a marker of bone resorption. Measured in serum. | From -10 minutes to 240 minutes. | 
| Bone formation | P1NP is a marker of bone formation. Measured in serum. | From -10 minutes to 240 minutes. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Parathyroid hormone | PTH is a bone marker | From -10 minutes to 240 minutes. | 
| Calcium | Measured in serum. | From -10 minutes to 240 minutes. | 
| GIP | Intact and total GIP. | From -10 minutes to 240 minutes. | 
| GLP-2 | Intact GLP-2 | From -10 minutes to 240 minutes. | 
| Glucose | Measured in serum. | From -10 minutes to 240 minutes. | 
| Insulin | Measured in serum. | From -10 minutes to 240 minutes. | 
| C-peptide | Measured in serum. | From -10 minutes to 240 minutes. | 
| Sclerostin | Bone marker. | From -10 minutes to 240 minutes. |
Proton Pump Inhibitors Use in Patients With Psoriasis

Study Overview
=================
Brief Summary
-----------------
Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

Detailed Description
-----------------
Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis. The study will assess the evolution of skin lesions in psoriasis patients using PPIs

Official Title
-----------------
Proton Pump Inhibitors Use in Patients With Psoriasis

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Drug: esomeprazole
* Drug: desonide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnostic of Psoriasis Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>Proton Pump Inhibitor esomeprazole 40 mg twice a day | Drug: esomeprazole<br>* esomex 40 mg twice daily<br>* Other names: esomex;|
| Active Comparator: Group B<br>desonide | Drug: desonide<br>* topical corticosteroid desonid 0,1% b.i.d<br>* Other names: corticosteroid;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy - Change from baseline in skin lesions at 5 months | Number of Participants With Treatment-Related Clinical Improvement of lesions Change From Baseline in skin lesions at 5 months | Baseline - 5 months |
Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis

Study Overview
=================
Brief Summary
-----------------
We aim at investigation the impact of chronic air pollution exposure on non-cystic fibrosis bronchiectasis outcome.

Detailed Description
-----------------
Patient files will be search for time of death and cause of death. Other variables will be collected: bacterial culture results, therapy, gender, age, etc. These data will be linked with pollution data: trafic load, distance to major road, etc.

Official Title
-----------------
Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis

Conditions
-----------------
Bronchiectasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HRCT diagnosis of bronchiectasis recurrent infections or chronic sputum production patients between 18 and 65 years old. Exclusion Criteria: Cystic Fibrosis Tumoral disease Traction bronchiectasis due to interstitial lung disease patients older than 65 years or younger than 18 years at recruitment COPD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death | From June 2006 till October 2012, enrolled patients' medical file will be screened if death has occurred. If so, cause of death will be search for in the patients' file. | 6 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-cystic fibrosis bronchiectasis
Risk and Incidence of Aortic Graft and Endograft Infection With BSI

Study Overview
=================
Brief Summary
-----------------
What is the risk of aortic vascular graft and endograft infection in patients with aortic vascular graft/endograft and bloodstream infection?

Detailed Description
-----------------
All patients with previous aortic vascular graft and endograft surgery between years 2010 and 2021 in four regions of south Sweden (Skåne, Halland, Kronoberg and Blekinge) will be included in the study. These patients will be evaluated for bloodstream infection (BSI) or not. For all patients with BSI, the risk of aortic vascular graft and endograft infection will be investigated. Aortic vascular graft and endograft infection will be determined by usage of the MAGIC-criteria. Risk factors for developing aortic vascular graft and endograft infection will be investigated, and if possible used to construct a risk score. This risk score could be used by clinicians to determine if bacteremic patients with aortic vascular grafts or endografts should be evaluated for aortic vascular graft and endograft infection.

Official Title
-----------------
Risk and Incidence of Aortic Graft and Endograft Infection in Patients With Bloodstream Infection, a Population Based Study in South Sweden

Conditions
-----------------
Aortic Infections and Inflammations

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previous aortic vascular graft or endograft infection with bloodstream infection. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aortic vascular graft or endograft infection | Determined by the MAGIC-criteria | At least 1 year follow-up |
Tracheal Intubation in Morbidly Obese (BMI>35) and in Lean (BMI<30) Patients Using McGrath MAC X-Blade

Study Overview
=================
Brief Summary
-----------------
80 lean (BMI<35) and morbidly obese (BMI>35) patients undergoing elective surgery were enrolled in this prospective ransomİzed study were intubated using McGrath MAC X-Blade. The demographic and airway variables of patients and insertion and intubation times with these dievices, need for optimisation maneuvers, hemodynamic changes and minör postoperative complications were recorded.

Detailed Description
-----------------
80 lean (BMI<35) and morbidly obese (BMI>35) patients undergoing elective surgery were enrolled in this prospective ransomİzed study were intubated using McGrath MAC X-Blade. The demographic and airway variables of patients were recorded. Airway management variables Cormack-Lehan grades, insertion and intubation times, need for optimization maneuvers ( cricoid pressure, re-inserting, drawback) , hemodynamic changes in heart rate , blood pressure and minor postoperative complications such as sore throat, dysphasia, hoarseness were recorded.

Official Title
-----------------
A Comparison of Morbidly Obese and Lean

Conditions
-----------------
Obesity, Morbid

Intervention / Treatment
-----------------
* Device: lean
* Device: obese


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 age <65 age bmı 35 undergoing elective surgery requiring endotracheal intubation Exclusion Criteria: -pregnant <18 and >65 years of age bmı<35 upper respiratory tract infection past ten days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: insertion time<br> | Device: lean<br>* Videolaryngoscope used in intubation<br>Device: obese<br>* Videolaryngoscope used in intubation<br>|
| Active Comparator: intubation time<br> | Device: lean<br>* Videolaryngoscope used in intubation<br>Device: obese<br>* Videolaryngoscope used in intubation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intubation time |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
videolaryngoscope, Airtraq, McGrath MAC, Morbid obesity, intubation
Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.

Official Title
-----------------
Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

Conditions
-----------------
N/A - Healthy Subjects

Intervention / Treatment
-----------------
* Drug: Apixaban
* Drug: Atenolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECGs), and clinical laboratory determinations Exclusion Criteria: Any significant acute or chronic medical illness, history of hypotension, history or evidence of abnormal bleeding or coagulation disorders, significant head injury within the last 2 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment A: Apixaban<br>Apixaban tablet by mouth on specified day | Drug: Apixaban<br> <br> |
| Experimental: Treatment B: Atenolol<br>Atenolol tablet by mouth on specified day | Drug: Atenolol<br> <br> |
| Experimental: Treatment C: Apixaban and Atenolol<br>Apixaban and Atenolol tablets by mouth on specified day | Drug: Apixaban<br> <br> Drug: Atenolol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apixaban and Atenolol plasma concentration | Blood samples for Atenolol PK were collected on days 1-3 of each period (Treatment B and C). Blood samples for Apixaban PK were collected on days 1-4 of each period (Treatment A and C) | Days 1-13 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and Tolerability based on adverse events (AE) reports and the results of vital sign measurements, electrocardiogram (ECGs), physical examinations, and clinical laboratory tests |  | Days 1-13 |
Young Adult Beverage and Health Study

Study Overview
=================
Brief Summary
-----------------
This study examines the impact of health signage on beverage consumption in a cafeteria.

Official Title
-----------------
Young Adult Beverage and Health Study

Conditions
-----------------
Diet Habit

Intervention / Treatment
-----------------
* Behavioral: Signage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergraduate student or staff member at specific university Age 18+ On meal plan if a student Works in specific cafeterias if staff Exclusion Criteria: Age <18 years Adults unable to consent or complete the written or online survey

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Comparison<br>Cohort of participants who regularly eat in cafeteria without health signage. | |
| Signage<br>Cohort of participants who regularly eat in cafeteria in which health signage is placed. | Behavioral: Signage<br>* Placement of signage discouraging consumption of beverages with added sugar<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in self-reported sugar-sweetened beverage consumption | Beverage frequency questionnaire assessing whether various beverages were consumed 4 or more times per day, 3 times per day, 2 times per day, 1 time per day, 4-6 times per week, 2-3 times per week, one time per week or less, or never in the last/current semester. | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cafeteria sugar-sweetened beverage usage | Based on inventory and syrup/beverage purchase data and customer counts. | 5 months |
Effects of Expiratory Pressure on Arterial Oxygenation During Hypoxia

Study Overview
=================
Brief Summary
-----------------
Altitude tolerance correlates with the level of oxygenation achieved. The aim of the present study is to investigate whether increased expiratory pressure within the thorax is able to improve oxygenation during hypoxic hypoxia.

Detailed Description
-----------------
Two types of procedures will be tested in a random order, interspaced by resting periods : threshold PEEP set at 5,10 and 15 cm of water and pursed leap breathing. Subjects will be tested at rest, and during light exercise (30% of sea level predicted VO2max). FiO2 will be set at 12.5% (4000 m). fc, VE, PETCO2, TA, ECG, cardiac output, and tissular oxygenation will be monitored.

Official Title
-----------------
Arterial Oxygenation During Hypoxia : Effects of an Added Expiratory Resistance

Conditions
-----------------
Hypoxia

Intervention / Treatment
-----------------
* Device: threshold PEEP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria : active (> 2 hrs/week physical activity) adult non smoking volunteers Exclusion Criteria : cardiac, respiratory, neuromuscular, metabolic pathology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy active subjects<br>with and without high altitude intolerance | Device: threshold PEEP<br>* Various set of pressures : 0, 5, 10 cm H20; pursed lips breathing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SpO2 | after three minutes of PEEP vs spontaneous breathing | mean over 1 minute | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| peripheral HbO2/DeoxyHb | after three minutes of PEEP / PLB vs. spontaneous breathing | 1 min | 
| cardiac output | after three min of PEEP vs. spontaneous breathing | mean over 1 min | 
| pattern of breathing (fR, VT, PETCO2) | after three min of PEEP vs. spontaneous breathing | 1 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypoxia, O2 diffusion and convection, cardiac output, PEEP, Effects of hypoxia
Comparison of Airtraq Versus MacIntosh Intubation Via Nasal Approach

Study Overview
=================
Brief Summary
-----------------
Time, success rate, and number of optimising maneuvers for tracheal intubation via the nasal approach are not different when Aitraq technique is used compared to a standard MacIntosh blade.

Detailed Description
-----------------
One hundred adult patients with an expected easy intubation and 100 patients with an expected difficult intubation are enrolled. Intubations are performed by two experienced fully boarded anesthesiologists. The design of the study is prospective and randomised.

Official Title
-----------------
Comparison of Airtraq vs. MacIntosh Intubation Via Nasal Approach

Conditions
-----------------
Tracheal Intubation

Intervention / Treatment
-----------------
* Device: Intubation
* Device: Airtraq


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Scheduled for nasal intubation Adult Exclusion Criteria: Age under 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1. Airtraq<br>Intubation with the use of the Airtraq technique | Device: Airtraq<br>* Intubation with the use of the Airtraq technique<br>* Other names: Aitraq, Prodol Meditec S.A., Vizcaya, Spain;|
| Active Comparator: 2. MacIntosh<br>Intubation using the standard MacIntosh blade | Device: Intubation<br>* Intubation using the standard MacIntosh blade<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time for intubation |  | 10 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success rate for intubation |  | 10 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nasal intubation, Aitraq, difficult intubation